IL291560A - il-15 conjugated peptides used in cancer therapy - Google Patents

il-15 conjugated peptides used in cancer therapy

Info

Publication number
IL291560A
IL291560A IL291560A IL29156022A IL291560A IL 291560 A IL291560 A IL 291560A IL 291560 A IL291560 A IL 291560A IL 29156022 A IL29156022 A IL 29156022A IL 291560 A IL291560 A IL 291560A
Authority
IL
Israel
Prior art keywords
treat cancer
peptides used
fusion peptides
fusion
cancer
Prior art date
Application number
IL291560A
Other languages
English (en)
Hebrew (he)
Original Assignee
Prostate Cancer Res Centre
King S College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prostate Cancer Res Centre, King S College London filed Critical Prostate Cancer Res Centre
Publication of IL291560A publication Critical patent/IL291560A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL291560A 2019-09-25 2022-03-21 il-15 conjugated peptides used in cancer therapy IL291560A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201913804A GB201913804D0 (en) 2019-09-25 2019-09-25 Fusion polypeptides
PCT/GB2020/052328 WO2021058973A1 (en) 2019-09-25 2020-09-25 Il-15 fusion peptides used to treat cancer

Publications (1)

Publication Number Publication Date
IL291560A true IL291560A (en) 2022-05-01

Family

ID=68425465

Family Applications (1)

Application Number Title Priority Date Filing Date
IL291560A IL291560A (en) 2019-09-25 2022-03-21 il-15 conjugated peptides used in cancer therapy

Country Status (9)

Country Link
US (1) US20220372097A1 (enExample)
EP (1) EP4034552A1 (enExample)
JP (1) JP2023502843A (enExample)
CN (1) CN114651014A (enExample)
AU (1) AU2020351698A1 (enExample)
CA (1) CA3155100A1 (enExample)
GB (1) GB201913804D0 (enExample)
IL (1) IL291560A (enExample)
WO (1) WO2021058973A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
GB202304385D0 (en) 2023-03-24 2023-05-10 Prostate Cancer Res Combinatorial IL-15 therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
GB9614871D0 (en) 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
US20070160578A1 (en) * 2005-12-14 2007-07-12 The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
GB0915519D0 (en) 2009-09-04 2009-10-07 King S College London Ntithrombotic compounds
WO2012054509A2 (en) * 2010-10-22 2012-04-26 Dana-Farber Cancer Institute, Inc. Discovery of regulatory t cells programmed to suppress an immune response
WO2018161026A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Il15 compositions and methods for immunotherapy
WO2019006472A1 (en) * 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
CA3086040A1 (en) * 2017-12-19 2019-06-27 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
AU2019228381B2 (en) * 2018-02-28 2021-12-16 Pfizer Inc. IL-15 variants and uses thereof
CA3090407A1 (en) * 2018-03-01 2019-09-06 Glycotope Gmbh Fusion protein constructs comprising an anti-muc1 antibody and il-15

Also Published As

Publication number Publication date
AU2020351698A1 (en) 2022-03-31
US20220372097A1 (en) 2022-11-24
EP4034552A1 (en) 2022-08-03
CN114651014A (zh) 2022-06-21
CA3155100A1 (en) 2021-04-01
JP2023502843A (ja) 2023-01-26
WO2021058973A1 (en) 2021-04-01
GB201913804D0 (en) 2019-11-06

Similar Documents

Publication Publication Date Title
GB201804255D0 (en) Macrophage-based therapy
ZA202102745B (en) Anti-ptk7 immune cell cancer therapy
ZA202102740B (en) Anti-liv1 immune cell cancer therapy
ZA202005847B (en) Cancer therapy
GB201900702D0 (en) Therapy
GB201819853D0 (en) Therapy
IL290520A (en) Medicinal peptides
GB201905780D0 (en) Cancer therapy
IL285144A (en) Medicinal peptides
IL291560A (en) il-15 conjugated peptides used in cancer therapy
IL277602A (en) P2RX7 modulators in therapy
GB201918752D0 (en) New therapy
GB201912191D0 (en) New therapy
GB201913957D0 (en) Cancer
GB201704909D0 (en) Cancer therapy
GB201821207D0 (en) Immunotherapy therapy
GB201817385D0 (en) Therapy
GB201901991D0 (en) Cancer
GB201818579D0 (en) New therapy
GB201814036D0 (en) New therapy
GB201919177D0 (en) Novel therapy
GB201912423D0 (en) Novel therapy
GB201919036D0 (en) Therapy
GB201916983D0 (en) Therapy
GB201914848D0 (en) Therapy